RAF signaling in neuroendocrine neoplasms: From bench to bedside

Nicola Fazio, Omar Abdel-Rahman, Francesca Spada, Salvatore Galdy, Sara De Dosso, Jaume Capdevila, Aldo Scarpa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to several phase II studies; however, very few agents progressed to phase III clinical trials. The RAF family of proteins belongs to the mitogen-activated protein kinase (MAPK) pathway, that has a role in several types of cancers, particularly related to BRAF mutations. Indeed BRAF inhibitors have been reported as being effective, mainly in melanoma. However, in neuroendocrine neoplasms BRAF mutations are extremely rare and RAF-1 activation has been reported to inhibit tumor growth in a pre-clinical setting. Therefore, in this field, RAF-1 activators rather than BRAF inhibitors should be clinically investigated. This article reviews the basic science as well as clinical data of RAF signaling in advanced neuroendocrine neoplasms with special emphasis on the potential role of both RAF activators and inhibitors.

Original languageEnglish
Pages (from-to)974-979
Number of pages6
JournalCancer Treatment Reviews
Volume40
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Neoplasms
Phase III Clinical Trials
Mutation
Biological Factors
Mitogen-Activated Protein Kinases
Melanoma
Incidence
Growth
Proteins
Therapeutics

Keywords

  • BRAF
  • Cell signaling
  • MAPK
  • Molecular targeted therapy
  • NET
  • Neuroendocrine neoplasms
  • Neuroendocrine tumors
  • RAF
  • RAF-1

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Fazio, N., Abdel-Rahman, O., Spada, F., Galdy, S., De Dosso, S., Capdevila, J., & Scarpa, A. (2014). RAF signaling in neuroendocrine neoplasms: From bench to bedside. Cancer Treatment Reviews, 40(8), 974-979. https://doi.org/10.1016/j.ctrv.2014.06.009

RAF signaling in neuroendocrine neoplasms : From bench to bedside. / Fazio, Nicola; Abdel-Rahman, Omar; Spada, Francesca; Galdy, Salvatore; De Dosso, Sara; Capdevila, Jaume; Scarpa, Aldo.

In: Cancer Treatment Reviews, Vol. 40, No. 8, 2014, p. 974-979.

Research output: Contribution to journalArticle

Fazio, N, Abdel-Rahman, O, Spada, F, Galdy, S, De Dosso, S, Capdevila, J & Scarpa, A 2014, 'RAF signaling in neuroendocrine neoplasms: From bench to bedside', Cancer Treatment Reviews, vol. 40, no. 8, pp. 974-979. https://doi.org/10.1016/j.ctrv.2014.06.009
Fazio, Nicola ; Abdel-Rahman, Omar ; Spada, Francesca ; Galdy, Salvatore ; De Dosso, Sara ; Capdevila, Jaume ; Scarpa, Aldo. / RAF signaling in neuroendocrine neoplasms : From bench to bedside. In: Cancer Treatment Reviews. 2014 ; Vol. 40, No. 8. pp. 974-979.
@article{b5398995ff6c4384b26b7cd49699a449,
title = "RAF signaling in neuroendocrine neoplasms: From bench to bedside",
abstract = "Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to several phase II studies; however, very few agents progressed to phase III clinical trials. The RAF family of proteins belongs to the mitogen-activated protein kinase (MAPK) pathway, that has a role in several types of cancers, particularly related to BRAF mutations. Indeed BRAF inhibitors have been reported as being effective, mainly in melanoma. However, in neuroendocrine neoplasms BRAF mutations are extremely rare and RAF-1 activation has been reported to inhibit tumor growth in a pre-clinical setting. Therefore, in this field, RAF-1 activators rather than BRAF inhibitors should be clinically investigated. This article reviews the basic science as well as clinical data of RAF signaling in advanced neuroendocrine neoplasms with special emphasis on the potential role of both RAF activators and inhibitors.",
keywords = "BRAF, Cell signaling, MAPK, Molecular targeted therapy, NET, Neuroendocrine neoplasms, Neuroendocrine tumors, RAF, RAF-1",
author = "Nicola Fazio and Omar Abdel-Rahman and Francesca Spada and Salvatore Galdy and {De Dosso}, Sara and Jaume Capdevila and Aldo Scarpa",
year = "2014",
doi = "10.1016/j.ctrv.2014.06.009",
language = "English",
volume = "40",
pages = "974--979",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - RAF signaling in neuroendocrine neoplasms

T2 - From bench to bedside

AU - Fazio, Nicola

AU - Abdel-Rahman, Omar

AU - Spada, Francesca

AU - Galdy, Salvatore

AU - De Dosso, Sara

AU - Capdevila, Jaume

AU - Scarpa, Aldo

PY - 2014

Y1 - 2014

N2 - Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to several phase II studies; however, very few agents progressed to phase III clinical trials. The RAF family of proteins belongs to the mitogen-activated protein kinase (MAPK) pathway, that has a role in several types of cancers, particularly related to BRAF mutations. Indeed BRAF inhibitors have been reported as being effective, mainly in melanoma. However, in neuroendocrine neoplasms BRAF mutations are extremely rare and RAF-1 activation has been reported to inhibit tumor growth in a pre-clinical setting. Therefore, in this field, RAF-1 activators rather than BRAF inhibitors should be clinically investigated. This article reviews the basic science as well as clinical data of RAF signaling in advanced neuroendocrine neoplasms with special emphasis on the potential role of both RAF activators and inhibitors.

AB - Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to several phase II studies; however, very few agents progressed to phase III clinical trials. The RAF family of proteins belongs to the mitogen-activated protein kinase (MAPK) pathway, that has a role in several types of cancers, particularly related to BRAF mutations. Indeed BRAF inhibitors have been reported as being effective, mainly in melanoma. However, in neuroendocrine neoplasms BRAF mutations are extremely rare and RAF-1 activation has been reported to inhibit tumor growth in a pre-clinical setting. Therefore, in this field, RAF-1 activators rather than BRAF inhibitors should be clinically investigated. This article reviews the basic science as well as clinical data of RAF signaling in advanced neuroendocrine neoplasms with special emphasis on the potential role of both RAF activators and inhibitors.

KW - BRAF

KW - Cell signaling

KW - MAPK

KW - Molecular targeted therapy

KW - NET

KW - Neuroendocrine neoplasms

KW - Neuroendocrine tumors

KW - RAF

KW - RAF-1

UR - http://www.scopus.com/inward/record.url?scp=84904791071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904791071&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2014.06.009

DO - 10.1016/j.ctrv.2014.06.009

M3 - Article

C2 - 24998490

AN - SCOPUS:84904791071

VL - 40

SP - 974

EP - 979

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 8

ER -